高级检索
当前位置: 首页 > 详情页

MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells

| 认领 | 导出 |

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Breast & Thyroid Surg, Shanghai 200072, Peoples R China [2]Shanghai Tongren Hosp, Dept Gen Surg, Shanghai 200336, Peoples R China
出处:
ISSN:

关键词: miR-96 FOXO1 papillary thyroid carcinoma K1 TPC1 cells

摘要:
MicroRNAs (miRNAs) are kind of small non-coding RNAs that negatively regulate gene expression at post-transcription level, and those non-coding RNAs appear to play a key role in tumorigenesis. The aim of this study was to investigate the biological role of miR-96 in papillary thyroid carcinoma (PTC) cell lines. We identified miR-96 to be up-regulated in PTC specimens in comparison to matched normal tissues by microRNA microarray and RT-qPCR analysis (P < 0.05). Next, to explore the potential function of miR-96, PTC cell lines K1 and TPC1 were transiently transfected with miR-96 mimics and inhibitor. Successful transfection being confirmed by RT-qPCR. Ectopic expression of miR-96 promoted proliferation and colony formation ability, and inhibited apoptosis of K1 and TPC1 cells, whereas down-regulated expression of miR-96 suppressed those functions when compared with the control cells. According to a computational prediction, FOXO1 maybe a potential target of miR-96. Luciferase assays revealed that miR-96 is directly targeted to both binding sites of FOXO1 3'-untranslated region (3'-UTR) and suppressed the FOXO1 expression, and subsequently inhibited the expression of Bim protein in PTC cells. Moreover, the expression of FOXO1 had an inverse correlation with expression of miR-96 in PTC specimens by RT-qPCR and western blot analysis. The data from the present study demonstrated that miR-96 can promote proliferation, and inhibit apoptosis in PTC cell lines K1 and TPC1, thus miR-96 may play an oncogenic role in PTC by inhibiting the FOXO1 and regulating AKT/FOXO1/Bim pathway, and it may serve as a novel therapeutic target for miRNA-based PTC therapy.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2014]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 病理学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 病理学
JCR分区:
出版当年[2013]版:
Q3 ONCOLOGY Q3 PATHOLOGY
最新[2023]版:
Q3 PATHOLOGY Q4 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2013版] 出版当年五年平均 出版前一年[2012版] 出版后一年[2014版]

第一作者:
第一作者机构: [1]Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Breast & Thyroid Surg, Shanghai 200072, Peoples R China [*1]Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Breast & Thyroid Surg,Zhabei Area, 301 Yanchang Rd, Shanghai 200072, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Breast & Thyroid Surg, Shanghai 200072, Peoples R China [*1]Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Breast & Thyroid Surg,Zhabei Area, 301 Yanchang Rd, Shanghai 200072, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:23453 今日访问量:6 总访问量:1282 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)